Have a feature idea you'd love to see implemented?
Let us know!
CLGN CollPlant Biotechnologies Ltd
Price (delayed)
$4.165
Market cap
$47.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.54
Enterprise value
$32.17M
collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our
Highlights
The company's net income has shrunk by 159% YoY and by 133% QoQ
The company's EPS has shrunk by 152% YoY and by 133% QoQ
Key stats
What are the main financial stats of CLGN
Market
Valuations
Earnings
Shares outstanding
11.45M
Market cap
$47.71M
Enterprise value
$32.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.3
Price to sales (P/S)
69.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.7
Revenue
$689,000
EBIT
-$17.96M
EBITDA
-$16.87M
Free cash flow
-$3.44M
Per share
Balance sheet
Liquidity
EPS
-$1.54
Free cash flow per share
-$0.3
Book value per share
$1.81
Revenue per share
$0.06
TBVPS
$2.31
Total assets
$26.57M
Total liabilities
$5.84M
Debt
$3.39M
Equity
$20.73M
Working capital
$17.09M
Debt to equity
0.16
Current ratio
6.27
Quick ratio
6.07
Net debt/EBITDA
0.92
Margins
Efficiency
Dividend
EBITDA margin
-2,448%
Gross margin
-209.4%
Net margin
-2,535.7%
Operating margin
-2,671.3%
Return on assets
-54.4%
Return on equity
-66%
Return on invested capital
-238.5%
Return on capital employed
-77%
Return on sales
-2,607.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLGN stock price
How has the CollPlant Biotechnologies stock price performed over time
Intraday
-1.54%
1 week
-2%
1 month
6.25%
1 year
-25.63%
YTD
-34.82%
QTD
-16.11%
Financial performance
How have CollPlant Biotechnologies's revenue and profit performed over time
Revenue
$689,000
Gross profit
-$1.44M
Operating income
-$18.41M
Net income
-$17.47M
Gross margin
-209.4%
Net margin
-2,535.7%
CollPlant Biotechnologies's operating income has shrunk by 163% YoY and by 121% QoQ
The company's net income has shrunk by 159% YoY and by 133% QoQ
CLGN's gross profit has plunged by 117% from the previous quarter and by 115% YoY
The revenue has plunged by 94% YoY and by 94% from the previous quarter
Growth
What is CollPlant Biotechnologies's growth rate over time
Valuation
What is CollPlant Biotechnologies stock price valuation
P/E
N/A
P/B
2.3
P/S
69.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.7
The company's EPS has shrunk by 152% YoY and by 133% QoQ
The P/B is 48% less than the 5-year quarterly average of 4.4 and 8% less than the last 4 quarters average of 2.5
The equity has contracted by 42% YoY and by 15% from the previous quarter
CLGN's price to sales (P/S) is 175% higher than its last 4 quarters average of 25.2 and 25% higher than its 5-year quarterly average of 55.3
The revenue has plunged by 94% YoY and by 94% from the previous quarter
Efficiency
How efficient is CollPlant Biotechnologies business performance
CollPlant Biotechnologies's ROE has plunged by 167% from the previous quarter
CLGN's ROA has dropped by 160% since the previous quarter
Dividends
What is CLGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLGN.
Financial health
How did CollPlant Biotechnologies financials performed over time
The current ratio has declined by 50% year-on-year and by 12% since the previous quarter
The quick ratio has contracted by 49% YoY and by 12% from the previous quarter
The debt is 84% less than the equity
CollPlant Biotechnologies's debt to equity has surged by 78% YoY and by 33% QoQ
The equity has contracted by 42% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.